NZ's Fisher & Paykel Healthcare jumps after Jefferies upgrades to 'buy'

Shares of New Zealand's Fisher & Paykel Healthcare FPH.NZ rise as much as 2.9% to NZ$35.43, their highest levels since February 21

Analysts at Jefferies see the medical equipment maker mitigating impact of 25% U.S. tariffs on Mexican imports

Brokerage upgrades the medical equipment maker to "buy" from "hold", raises price target to NZ$39.40 from NZ$35.25

"FPH's New Zealand-manufactured products already FDA approved, the option to substitute Mexican with NZ imports is only limited by re-routing and freight lead times," Jefferies says

Adds that FPH's three months of inventory available in the U.S. and potential to increase prices will help further moderate the impact of tariffs in FY26

Two of 12 analysts rate the stock "buy", seven "hold" and three "sell" or lower; their median PT is NZ$37.00 – data compiled by LSEG

Stock trims YTD losses to 7.7%, including the day's move